Loading…
Loading…
See exactly how EEV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EEV and 80,000+ other tickers.
The ProShares UltraShort MSCI Emerging Markets fund endeavors to generate daily investment results that mirror an amplified inverse (-2x) of the MSCI Emerging Markets Index's daily performance. These results are calculated prior to the subtraction of any fees and operating expenses.
Following the 2024 U.S. election, there has been a great deal of speculation about how a second Trump administration will set policies that have an impact on the economy. Some have taken a strongly optimistic view of what's to come—a recent Goldman Sachs report suggested that the likelihood of a recession has diminished along with inflation levels and that anticipated changes to tariffs, immigration, and other policies are not likely to dampen economic growth.
Emerging markets continued to expand at a solid pace midway into the first quarter of 2024, supported by broad-based expansion across both manufacturing and service sectors.
Emerging markets have taken solace in the view that the U.S. hiking cycle is over, helping deliver strong returns in 2023. Slowing global inflation has been due to sharply lower core goods inflation, while service prices have remained stickier.
Emerging markets will also be looking closely at economic conditions in mainland China, which will be a key determinant of broader emerging market growth in 2024. A key reason for diverging emerging and developed market performance was the marked variation in demand conditions.
BOSTON--( BUSINESS WIRE )--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada's program for DM1, ENTR-701, which is in late-stage preclinical development.